<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11953390</article-id><article-id pub-id-type="pmcid-ver">PMC11953390.1</article-id><article-id pub-id-type="pmcaid">11953390</article-id><article-id pub-id-type="pmcaiid">11953390</article-id><article-id pub-id-type="pmid">40155631</article-id><article-id pub-id-type="doi">10.1038/s41598-025-94761-0</article-id><article-id pub-id-type="publisher-id">94761</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Identification of therapeutic targets for chronic kidney disease through Mendelian randomization analysis of druggable genes</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Liang</surname><given-names initials="RS">Run-Sen</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Su</surname><given-names initials="JQ">Jin-Qi</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="XQ">Xiang-Qi</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Q">Qi</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cai</surname><given-names initials="YM">Yong-Mei</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="HY">Hong-Yong</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tang</surname><given-names initials="JX">Ji-Xin</given-names></name><address><email>tangjixin@gdmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Yao</surname><given-names initials="CW">Cui-Wei</given-names></name><address><email>yaocuiwei@gdmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04k5rxe29</institution-id><institution-id institution-id-type="GRID">grid.410560.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1760 3078</institution-id><institution>Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases, Key Laboratory of Prevention and Management of Chronic Kidney Diseases of Zhanjiang City, Institute of Nephrology, </institution><institution>Affiliated Hospital of Guangdong Medical University, </institution></institution-wrap>Zhanjiang, Guangdong China </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>10779</elocation-id><history><date date-type="received"><day>14</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>29</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-30 10:25:15.913"><day>30</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_94761.pdf"/><abstract id="Abs1"><p id="Par1">Chronic Kidney Disease (CKD) is a multifaceted and gradually advancing condition characterized by a complex pathogenesis. The current therapeutic options for CKD remain limited in efficacy. Consequently, the identification and exploration of novel drug targets for CKD are of paramount importance. We identified cis-expression quantitative trait loci (cis-eQTLs) with potential as drug targets from the eQTLGen Consortium database to serve as the exposure. For the outcome, we utilized a genome-wide association study (GWAS) of chronic kidney disease (CKD) from the FinnGen database, which comprised a case group of 11,265 individuals and a control group of 436,208 individuals. MR analysis was employed to investigate druggable genes closely associated with CKD. Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted to elucidate the functional roles of these significant genes. Finally, a colocalization analysis was conducted to determine the likelihood that a cis-eQTL for a druggable gene and CKD share a causal variant. The expression of 12 genes was found to be significantly associated with CKD risk, with a false discovery rate (FDR) of less than 0.05. GO and KEGG enrichment analyses indicated that these genes are primarily involved in the regulation of MAP kinase activity, regulation of protein serine/threonine kinase activity, Gap junction, Platelet activation and Oxytocin signaling pathway. The colocalization analysis results suggested that CKD and the TUBB gene may share a causal variant, with a posterior probability (PP.H4) exceeding 80% (TUBB: 97.27%). Compelling statistical evidence indicates that TUBB represents the most promising pharmacological target for the treatment of CKD. This study not only identifies potential therapeutic targets but also offers valuable insights for future drug development in the context of CKD.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-94761-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chronic kidney disease</kwd><kwd>TUBB</kwd><kwd>Druggable genes</kwd><kwd>Mendelian randomization analysis</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Data mining</kwd><kwd>Drug discovery</kwd><kwd>Genetics</kwd><kwd>Nephrology</kwd></kwd-group><funding-group><award-group><funding-source><institution>The Natural Science Foundation of Guangdong Province</institution></funding-source><award-id>2023A1515012187, 2024A1515030281</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>National Clinical Key Specialty Construction Project (Institute of Nephrology, Affiliated Hospital of Guangdong Medical University), The Affiliated Hospital of Guangdong Medical University funded the research of high-level talents</institution></funding-source><award-id>10403Z20180001</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Zhanjiang City Science and Technology Development Special Funds Competitive Allocation Project</institution></funding-source><award-id>2021A05083</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Chronic Kidney Disease (CKD) is a progressive condition affecting over 800&#160;million individuals globally<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. It is defined by a persistent estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73&#160;m&#178; body surface area, or urinary albumin excretion equal to or greater than 30&#160;mg/day, or both, sustained for a duration exceeding three months<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Historically, the management of CKD primarily focused on delaying renal failure, implementing end-stage dialysis, or pursuing renal transplantation<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. However, recent advancements in the field have led researchers to explore pharmacological interventions, such as empagliflozin, which has shown promise in decelerating CKD progression and mitigating cardiovascular risks associated with the condition<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Despite advancements in medical research, effective treatments for CKD remain elusive. Consequently, the identification and exploration of novel drug targets for CKD treatment are imperative.</p><p id="Par6">Expression quantitative trait loci (eQTLs), which are single nucleotide polymorphisms (SNPs) that influence gene expression levels, present a promising avenue for this endeavor. Utilizing MR analysis of druggable genes, cis-eQTLs&#8212;SNPs located in the proximal genomic regions of target genes and closely associated with their expression&#8212;serve as instrumental variables (IVs) to elucidate causal relationships between druggable genes and CKD. This approach facilitates the identification of potential drug targets for CKD treatment. This approach has also found extensive application in the investigation of various other diseases<sup><xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par7">Mendelian Randomization (MR), a statistical technique that leverages genetic variation as an instrumental variable, has demonstrated significant potential in recent years for causal inference in the context of complex diseases<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. By utilizing genetic variants that exhibit strong correlations with exposure factors as IVs, MR facilitates the assessment of causal relationships between exposure factors and outcomes, thereby mitigating the influence of confounding variables. Consequently, MR analyses is frequently employed to evaluate etiological inferences in epidemiological research<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. Importantly, the effectiveness of MR analyses parallels that of randomized controlled trials, albeit with reduced bias and the elimination of reverse causality (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>)<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par8">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>The principle of Mendelian randomization analysis is shown in the figure, where instrumental variables can represent exposure (druggable gene), are independent of confounding factors, and do not directly affect outcomes (Chronic kidney disease).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e263" position="float" orientation="portrait" xlink:href="41598_2025_94761_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par9">In this MR analysis, we selected cis-expression quantitative trait loci (cis-eQTL) of druggable genes as the exposure variable and employed genome-wide association study (GWAS) data for CKD from the FinnGen database as the outcome variable. This approach was designed to elucidate the complex relationship between the expression of druggable genes and CKD. To identify the most suitable SNPs as instrumental variables, we conducted association analyses of the exposure factors and established stringent inclusion and exclusion criteria. A series of sensitivity analyses was implemented in order to ensure the robustness and reliability of the MR analysis. Furthermore, to elucidate the functional roles of the significant genes identified through MR analysis in terms of cellular composition, biological processes, and molecular functions, as well as to interpret the biological pathways they are involved in according to the Kyoto Encyclopedia of Genes and Genomes (KEGG), we performed comprehensive functional annotations. We conducted Gene Ontology (GO) and KEGG enrichment analyses on these significant genes, and provided detailed information regarding their chromosomal positions. Additionally, we performed colocalization analysis to evaluate whether cis-eQTL and CKD share the same causal variants. The overall design idea is detailed in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>.</p><p id="Par10">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>The overall design of this study is shown in the figure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e282" position="float" orientation="portrait" xlink:href="41598_2025_94761_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>Data sources</title><p id="Par11">By comparing the sequences and structures of proteins present in human blood with those of currently identified drug target proteins, scientists identified several proteins that exhibit structural similarity to known drug targets and possess the potential to be modulated by drug-like small molecules. Consequently, scientists identified a specific group of genes for further investigation<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Finan identified 1,427 genes encoding drug targets that have been approved or are in the clinical phase, 682 genes encoding proteins that bind to known drug molecules or are similar to approved drug targets, and 2,370 genes that are members of a family of key druggable genes or encode proteins that are distantly similar to approved drug targets<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. These 4,479 druggable genes have also been utilized by researchers to investigate potential therapeutic targets for pulmonary fibrosis (Supplementary Material: Table <xref rid="MOESM1" ref-type="media">S1</xref>)<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. (Supplementary Material: Table <xref rid="MOESM1" ref-type="media">S1</xref>). We queried the eQTLGen Consortium database for these 4,479 druggable genes and retrieved blood cis-eQTL data for 2,888 of them<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. The eQTL data facilitated the identification of genetic variants associated with gene expression levels in blood samples, specifically those variants located within 1&#160;Mb of the central location of each gene.</p><p id="Par12">FinnGen is a well-known and large database, and FinnGen provides genetic insights from a phenotypically well-defined and isolated population<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. The CKD outcome data were derived from the FinnGen database, which collected information on 447,473 individuals, including 11,265 in the case group and 436,208 in the control group.</p></sec><sec id="Sec6"><title>Selection of instrumental variables</title><p id="Par16">Reliable and accurate instrumental variables are characterized by three distinctive features:<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> a very strong association with the exposure<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>, no relationship with confounders other than the exposure, and<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> the absence of horizontal pleiotropy. It is essential to note that horizontal pleiotropy should be entirely absent in MR analyses. To identify IVs meeting these criteria, we conducted a rigorous screening of each druggable gene. Initially, we performed association analyses to select SNPs from the cis-eQTL data, ensuring that only SNPs with P-values below the genome-wide significance threshold (5.0&#8201;&#215;&#8201;10<sup>&#8722;&#8201;8</sup>) were considered. Secondly, to mitigate the knock-on disequilibrium effects of these SNPs, we utilized the &#8220;TwoSampleMR&#8221; package in the R programming language to set the linkage disequilibrium (LD) threshold to R&#178; &lt; 0.1, using data from the 1000 Genomes Project (EUR population) with an aggregation distance of 10,000 kb<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. In addition, we calculated the proportion of variance explained (R<sup>2</sup>) and the F statistic to quantify the strength of the tool with the following equations: R<sup>2</sup>&#8201;=&#8201;2 &#215; MAF &#215; (1 - MAF) &#215; &#946;<sup>2</sup>, and F&#8201;=&#8201;R<sup>2</sup>(n-k-1)/ k(1-R<sup>2</sup>), where &#8220;MAF&#8221; is the SNP used as the IV secondary allele frequency, &#8220;n&#8221; is the sample size, &#8220;k&#8221; is the number of IVs used<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. To avoid weak IV bias, we selected SNPs with F&#8201;&gt;&#8201;10 as the IVs we analysed.</p></sec><sec id="Sec7"><title>Mendelian randomization analysis</title><p id="Par17">MR analyses were conducted using the &#8220;TwoSampleMR&#8221; package in R (version 4.4.1). For the MR analysis, the Wald ratio method was employed when a single SNP served as the IV. When the IV comprised two or more SNPs, we applied five different methods: inverse variance weighting (IVW), MR-Egger, weighted median, simple mode, and weighted mode. We used the IVW method as the primary analysis method because previous studies have shown that the IVW method is more conservative but more robust<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. To account for multiple testing, we applied the False Discovery Rate (FDR) correction to identify significant MR analysis results. Additionally, to ensure the robustness of our findings, we employed several methods for sensitivity analyses. Potential heterogeneity of IVs was assessed using Cochrane&#8217;s Q test<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Heterogeneity was considered absent if the p-value of the Cochrane Q test exceeded 0.05. Potential pleiotropy between exposure and outcome was examined using MR-Egger regression. Pleiotropy was considered absent if the p-value for the MR-Egger regression intercept was greater than 0.05<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>.</p></sec><sec id="Sec8"><title>Colocalization</title><p id="Par18">For druggable genes showing significant MR results, colocalization analysis was performed using the R package &#8220;coloc&#8220;<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. The default a priori probabilities were P1&#8201;=&#8201;1.0&#8201;&#215;&#8201;10<sup>&#8722;&#8201;4</sup>, P2&#8201;=&#8201;1.0&#8201;&#215;&#8201;10<sup>&#8722;&#8201;4</sup>, and P12&#8201;=&#8201;1.0&#8201;&#215;&#8201;10<sup>&#8722;&#8201;5</sup>, indicating that the SNPs were associated with the expression of the druggable genes, the outcome, or both, respectively. Posterior probabilities for the following five hypotheses were generated from the colocalization analysis: PPH 0, not associated with the expression or outcome of a druggable gene; PPH 1, associated with the expression of a druggable gene but not with the outcome; PPH 2, associated with the outcome but not with the expression of a druggable gene; PPH 3, associated with the expression and outcome of a druggable gene with a different causal variant; and PPH 4, association with expression of the druggable genes and outcome, with a shared causal variant. PPH 4&#8201;&gt;&#8201;0.80 was considered strong.</p></sec><sec id="Sec9"><title>Gene function and pathway enrichment analysis</title><p id="Par19">GO is the world&#8217;s largest source of information on gene function. This knowledge is both human-readable and machine-readable, and is the basis for large-scale computational analyses<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. KEGG is a database for understanding high-level functions and utilities of biological systems from molecular-level information<sup><xref ref-type="bibr" rid="CR22">22</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref></sup>. For biological process and pathway enrichment analyses, KEGG and GO analyses were performed using the R &#8220;clusterProfiler&#8221; software package. Finally, the R &#8220;circlize&#8221; package was used<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> to display information on the location of these genes on the corresponding chromosomes.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Twelve significant genes were identified by MR analysis of druggable genes</title><p id="Par20">We employed the IVW method as the primary analytical approach. Sixteen druggable genes exhibited a strong association with the development of CKD at a FDR of less than 0.05. These genes are PTPN22, KSR1, MAP2K5, CASP9, C4A, S100B, MYLK4, CHSY1, TUBB, C4B, XYLT1, DHFR, GUCY1B2, CXCR1, CD96, and VAMP8. To assess the pleiotropy of these 16 significant genes, we utilized MR-Egger regression. The intercept p-value for &#8220;S100B&#8221; was less than 0.05, indicating the presence of horizontal pleiotropy. Conversely, the intercept p-values for the remaining 15 significant genes were greater than 0.05, suggesting no evidence of horizontal pleiotropy for these genes. The potential heterogeneity of IVs was assessed using Cochrane&#8217;s Q-test. The results indicated significant heterogeneity for the IVs associated with &#8220;C4A,&#8221; &#8220;C4B,&#8221; and &#8220;XYLT1,&#8221; while no evidence of heterogeneity was found for the other significant genes. To ensure the reliability of our findings, we did not accept the presence of horizontal pleiotropy and heterogeneity. Consequently, we concluded that a causal association exists between 12 genes&#8212;PTPN22, KSR1, MAP2K5, CASP9, MYLK4, CHSY1, TUBB, DHFR, GUCY1B2, CXCR1, CD96, and VAMP8&#8212;and CKD (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). It is worth mentioning that the MR-PRESSO test revealed no evidence of pleiotropy among these 12 significant genes.</p><p id="Par21">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>The 12 druggable genes are closely related to the risk of CKD after FDR correction. If OR is greater than 1, the gene is considered to be positively correlated with the occurrence of CKD, and if it is less than 1, it is considered to be negatively correlated. FDR is the corrected p-value, and FDR is greater than 0.05, which is considered statistically significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e423" position="float" orientation="portrait" xlink:href="41598_2025_94761_Fig3_HTML.jpg"/></fig>
</p><p id="Par22">Among these 12 significant genes, TUBB (OR: 1.2352; 95% CI: 1.1305&#8211;1.3496; <italic toggle="yes">FDR</italic>&#8201;=&#8201;0.0085), PTPN22 (OR: 1.2897; 95% CI: 1.1893&#8211;1.3985; <italic toggle="yes">FDR</italic>&#8201;&lt;&#8201;0.001), MAP2K5 (OR: 1.1055; 95% CI: 1.0679&#8211;1.1445; <italic toggle="yes">FDR</italic>&#8201;&lt;&#8201;0.001), CHSY1 (OR: 1.1152; 95% CI: 1.0667&#8211;1.1659; <italic toggle="yes">FDR</italic>&#8201;=&#8201;0.0044), DHFR (OR: 1.0390; 95% CI: 1.0214&#8211;1.0570; <italic toggle="yes">FDR</italic>&#8201;=&#8201;0.0347), CXCR1 (OR: 1.1188; 95% CI: 1.0634&#8211;1.1771; <italic toggle="yes">FDR</italic>&#8201;=&#8201;0.0430) and CD96 (OR: 1.0945; 95% CI: 1.0505&#8211;1.1404; <italic toggle="yes">FDR</italic>&#8201;=&#8201;0.0475) expression were positively correlated with the risk of CKD. KSR1 (OR: 0.8809; 95% CI: 0.8441&#8211;0.9192; <italic toggle="yes">FDR</italic>&#8201;&lt;&#8201;0.001), CASP9 (OR: 0.8782; 95% CI: 0.8389&#8211;0.9195; <italic toggle="yes">FDR</italic>&#8201;&lt;&#8201;0.001), MYLK4 (OR: 0.9078; 95% CI: 0.8744&#8211;0.9423; <italic toggle="yes">FDR</italic>&#8201;=&#8201;0.0011), GUCY1B2 (OR: 0.9068; 95% CI: 0.8679&#8211;0.9475; <italic toggle="yes">FDR</italic>&#8201;=&#8201;0.0359) and VAMP8 (OR: 0.9215; 95% CI: 0.8879&#8211;0.9565; <italic toggle="yes">FDR</italic>&#8201;=&#8201;0.0489) expression were negatively associated with CKD risk. (Information on the IVs used for these significant genes is detailed in Supplementary Material Table S2, and the results of MR analyses are detailed in Supplementary Material Table S3)</p></sec><sec id="Sec12"><title>Colocalization analysis of 12 significant genes</title><p id="Par23">Colocalization analysis can provide additional evidence for Mendelian randomization analysis, suggesting that associations between instrumental variables used for analysis and outcomes may be causal. Colocalization supports both an association between genetic variation and exposure and an association between exposure and outcome. When colocalization analyses show positive results, specific genetic variants share the same genetic location as signals associated with both exposure and outcome, this strengthens the belief that the association is due to genetic variants directly affecting exposure, and thus outcome. In addition, it reduces the likelihood of pleiotropy to some extent.</p><p id="Par24">In order to strengthen the evidence for an association between these key genes and CKD. For the 12 genes, we performed colocalization analyses to estimate the likelihood that the cis-eQTL and CKD results share a causal variant. The result of colocalization analysis indicated that CKD and TUBB genes might share a causal variant, with PP.H4 exceeding 0.80% (TUBB: 97.27%).</p><p id="Par25">Consequently, based on MR and colocalization analyses, we infer that TUBB is statistically likely to be a potential drug target for CKD treatment. (For details of the results of significant gene colocalization analysis, see Table S4 in the Supplementary Material)</p></sec><sec id="Sec13"><title>Demonstrate information about key genes on the corresponding chromosome</title><p id="Par26">The position of a gene on a chromosome may be related to its function, expression regulation, and interactions with other genes. By analyzing the chromosomal location of genes, we can obtain clues about their potential involvement in specific biological processes or pathways. Besides, many genetic disorders are associated with abnormalities in specific genes or gene clusters on chromosomes. Knowing the chromosomal location of these genes helps identify genetic variations related to diseases, providing important information for disease diagnosis, treatment, and prevention. Moreover, chromosomes are carriers of genetic information, and their structure, organization, and evolution are crucial for understanding the functional and evolutionary history of an organism&#8217;s genome. By analyzing the chromosomal location of genes, we can obtain clues about genome structure, chromosomal rearrangements, and evolutionary events. So, we show the information of the starting position of the remarkable genes on specific chromosomes. For example, the TUBB gene is located on chromosome 6 in the segment 30,687,978&#8211;30,693,203, and the PTPN22 gene is located on chromosome 1 in the segment 114,356,433&#8211;1,144,414,381 (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). (Seeing Supplementary Material Table <xref rid="MOESM1" ref-type="media">S1</xref> for details).</p><p id="Par27">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>This figure shows the relationship between significant genes and chromosome positions. For example, TUBB is located on chromosome 6.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e491" position="float" orientation="portrait" xlink:href="41598_2025_94761_Fig4_HTML.jpg"/></fig>
</p></sec><sec id="Sec56"><title>Analysis of specific biological processes, functional classes and signalling pathways corresponding to key genes by GO/KEGG enrichment</title><p id="Par29">GO enrichment analysis showed that in the Biological Process module, these genes were mainly enriched on regulation of MAP kinase activity and regulation of protein serine/threonine kinase activity. In the Cellular Component module, these genes were mainly enriched in primary lysosome. In the molecular Function Module, these genes were mainly enriched on protein serine kinase activity (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). KEGG pathway analyses showed that these genes were mainly enriched on Gap junction, Platelet activation and Oxytocin signaling pathway (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). (For details of the results of GO and KEGG enrichment analyses, please refer to Table S5 and Table S6 in the Supplementary Material.)</p><p id="Par30">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>This figure shows the results of GO enrichment analysis of 12 significant genes. For example, in the Biological Process module, there are three significant genes enriched in the regulation of MAP kinase activity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e511" position="float" orientation="portrait" xlink:href="41598_2025_94761_Fig5_HTML.jpg"/></fig>
</p><p id="Par31">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>This figure shows the results of KEGG enrichment analysis of 12 significant genes. For example, there are two significant genes enriched in Gap junction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e521" position="float" orientation="portrait" xlink:href="41598_2025_94761_Fig6_HTML.jpg"/></fig>
</p><p id="Par32">Notably, TUBB was pathway linked to Cellular community - eukaryotes, Infectious disease/bacterial, and Cellular Processes. In GO enrichment analysis, TUBB was associated with natural killer cell mediated immunity, leukocyte mediated immunity, lymphocyte mediated immunity, primary lysosome, azurophil granule, nuclear envelope lumen, spindle, intercellular bridge, GTPase activating protein binding, MHC class I protein binding, and MHC protein binding and other related.</p></sec></sec><sec id="Sec14"><title>Discussion</title><p id="Par33">In this study, we found that the expression of 12 genes was closely related to CKD. For genes demonstrating significant associations in the MR analysis, we performed a comprehensive suite of sensitivity analyses and functional assessments. These included Cochrane&#8217;s Q-test, MR-Egger regression, colocalization analysis, and GO and KEGG enrichment analyses. Our findings revealed a strong correlation between the expression of the TUBB gene and CKD. MR analysis of druggable genes, along with colocalization analysis, has yielded compelling evidence suggesting that TUBB is a potential therapeutic target for CKD.</p><p id="Par34">The TUBB gene encodes &#946;-tubulin, a structural component of microtubules that binds to &#945;-tubulin to form a heterodimer, which subsequently contributes to microtubule assembly<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Microtubules (MTs) have been characterized as long, hollow polymers with a diameter of 25&#160;nm and lengths ranging from less than 1&#160;&#956;m to over 100&#160;&#956;m. They were initially described as consisting of approximately 13 linear protofilaments, forming a polymer with a fast-growing positive end (exposed &#946;-tubulin) and a slow-growing negative end (exposed &#945;-tubulin)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. MTs are integral to the formation of cellular structures and the regulation of cellular functions, such as cell polarity and morphology, chromosome segregation during cell division, and the localization and transport of organelles<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Furthermore, MTs facilitate intracellular transport, assemble into larger structures with the aid of auxiliary proteins, and interact with various cell types to establish mature networks<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. It has been proposed that microtubule-targeting compounds inhibit microtubule polymerization, thereby causing an imbalance in microtubule dynamics. This disruption results in spindle apparatus damage, cell cycle arrest, and ultimately, tumor cell death<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Consequently, compounds that target microtubules are capable of inhibiting microtubule polymerization. It is apparent that these compounds can interfere with a range of critical cellular processes<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Among the proteins constituting microtubules, &#946;-tubulin is particularly significant. During microtubule polymerization, only the &#946;-tubulin subunit is capable of hydrolyzing GTP following the incorporation of microtubule dimers<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. This underscores the critical role of TUBB and its encoded &#946;-tubulin proteins in regulating cell proliferation, differentiation, and human immunity.</p><p id="Par35">Microtubule-targeting agents (MTAs) developed based on &#946;-tubulin proteins have a longstanding history and are considered among the earliest anti-cancer drugs<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. For instance, compounds such as vincristine, vinblastine, and vindesine target the Vinca domain located at the inter-dimer interface between two longitudinally aligned tubulin dimers within the &#946;-tubulin monomer<sup><xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref></sup>. Additionally, colchicine, benzimidazoles, and combretastatins interact with the colchicine binding sites situated in the deep pocket between &#945;&#946;-tubulin dimers within &#946;-tubulin monomers<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Furthermore, binding to the Taxane site of &#946;-tubulin monomers in the inner lumen of MTs stabilizes the MT lattice. Consequently, MT-stabilizing agents such as paclitaxel and epoxomicin have been developed<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Secondly, Maytansine and Spongistatin interact near the Vinca site on the exposed pocket of &#946;-tubulin<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>. Similarly, the compounds Laulimalide and Peloruside target &#946;-tubulin protein pockets oriented towards the exterior of microtubules (MTs)<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>. In 2021, the Gatorbulin site was identified, located within the &#945;-tubulin subunit, between &#945;- and &#946;-tubulin, and proximal to the colchicine site. This site functions to form a wedge between two longitudinally aligned MT dimers at the MT terminus<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Recently, a novel compound named Cevipabulin has been reported to bind to this pocket<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. The numerous sites of targeted drug development, whether currently known or unknown, associated with TUBB present substantial opportunities for TUBB to be considered a potential drug target in CKD.</p><p id="Par36">As discussed above, TUBB gene expression produces &#946; - tubulin, which is involved in the composition of microtubules. Meanwhile, microtubule associated proteins (MAPs) interact with microtubules, such as participating in microtubule binding, regulating microtubule stability, polymerization, and depolymerization processes. They interact with each other and jointly participate in maintaining the cytoskeleton structure and cell morphology within the cell<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. This is similar to our GO/KEGG enrichment analysis results, where in the Biological process module, these genes are mainly enriched in the regulation of MAP kinase activity. The relationship between GTPase activating protein (GAP) and microtubule proteins is close, and the microtubule network formed by the &#946; - microtubule protein encoded by the TUBB gene can serve as a transport track and localization platform for signaling molecules<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. This is similar to the results of our KEGG enrichment analysis, which mainly concentrates on the Gap junction.</p><p id="Par37">These &#946;-tubulin protein-based microtubule-targeting agents (MTAs) play a crucial role in tumor treatment by disrupting microtubule homeostasis within the spindle apparatus, thereby activating mitotic checkpoints. This disruption arrests cells at the mid-stage of mitosis, ultimately leading to cell death through apoptosis<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. Additionally, these agents have demonstrated efficacy against parasites<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Recent research has indicated that TUBB, a microtubule protein, may play a role in the pathological mechanisms underlying various renal diseases, including tubulointerstitial disease and renal fibrosis. For instance, Sang et al. demonstrated that the inhibition of microtubule dynamics hinders the repair of renal ischemia/reperfusion injury and promotes renal fibrosis<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Additionally, Yang et al. identified &#946;-tubulin as a serum marker for renal clear cell carcinoma, noting that this type of carcinoma is associated with elevated TUBB expression<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Although there is a paucity of comprehensive studies specifically addressing the relationship between TUBB and CKD, emerging research has increasingly concentrated on the interplay between MTs and their associated proteins in the context of CKD. A cross-sectional study has identified &#946;-tubulin as a potential biomarker for cognitive impairment in CKD patients<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Additionally, recent findings indicate that the long non-coding RNA (lncRNA) mini-nuclear host gene 12 exacerbates inflammation and apoptosis while inhibiting autophagy in acute kidney injury by upregulating TUBB expression<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. This finding aligns with the results of our analysis, which demonstrated a positive association between TUBB expression and CKD risk. Consequently, we propose that TUBB represents a potential therapeutic target for CKD, meriting further in-depth investigation into its underlying mechanisms. Apart from TUBB, several other potential targets were identified (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Although these additional significant genes were not corroborated by colocalization analysis, the important value of them cannot be entirely dismissed, and they continue to present a broad spectrum of possibilities for CKD drug development.</p><p id="Par38">Despite our rigorous analytical approach, which included the exclusion of results exhibiting heterogeneity and pleiotropy (including horizontal pleiotropy), our study has certain limitations. Firstly, our findings are based on statistical extrapolation, which may not fully capture the complexity of real-world scenarios where other confounding factors may interfere. Consequently, our results cannot entirely substitute for basic or clinical trials, nor can they guarantee the actual efficacy of the drug. Therefore, further basic and clinical research is warranted to elucidate the mechanisms and effects of TUBB on CKD. Besides, the current analysis is ethnically constrained, which may restrict the generalizability of our findings to other populations. Importantly, our study offers significant insights and guidance for advancing research on identifying drug targets for CKD.</p></sec><sec id="Sec15"><title>Conclusion</title><p id="Par39">The causal relationship established through MR analysis and CKD suggests new avenues for targeted drug research. In summary, our MR analysis indicates that TUBB may serve as a potential target for reducing CKD risk.</p></sec><sec id="Sec16" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_94761_MOESM1_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Run-Sen Liang and Jin-Qi Su contributed equally to this work.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Run-Sen Liang and Jin-Qi Su : Writing &#8211; original draft, Validation, Methodology, Data curation. Ji-Xin Tang and Cui-Wei Yao:Writing &#8211; review &amp; editing, Resources, Project administration. Xiang-Qi Wu, Qi Wang, Yong-Mei Cai and Hong-Yong Su: Writing &#8211; review &amp; editing, Validation, Software, Methodology, Data curation.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by grants from the Natural Science Foundation of Guangdong Province (2023A1515012187, 2024A1515030281), Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases (2022B121203003), Discipline Construction Project of Guangdong Medical University (4SG21229G), Zhanjiang City Science and Technology Development Special Funds Competitive Allocation Project (2021A05083), Zhanjiang Science and Technology Project (2019A01027), National Clinical Key Specialty Construction Project (Institute of Nephrology, Affiliated Hospital of Guangdong Medical University), The Affiliated Hospital of Guangdong Medical University funded the research of high-level talents(10403Z20180001).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The cis-eQTL data were obtained from the eQTLGen Consortium. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.eqtlgen.org/cis-eqtls.html">https://www.eqtlgen.org/cis-eqtls.html</ext-link>). The CKD data were obtained from the FinnGen. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.finngen.fi/en/access_results">https://www.finngen.fi/en/access_results</ext-link>). All data used in this study are publicly available and listed in Supplementary Material.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethical statement</title><p id="Par460">The study protocol received approval from the Medical Ethics Committee of the Affiliated Hospital of Guangdong Medical University.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par46">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovesdy</surname><given-names>CP</given-names></name></person-group><article-title>Epidemiology of chronic kidney disease: an update 2022</article-title><source>Kidney Int. Suppl. (2011)</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">35529086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kisu.2021.11.003</pub-id><pub-id pub-id-type="pmcid">PMC9073222</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Kovesdy, C. P. Epidemiology of chronic kidney disease: an update 2022. <italic toggle="yes">Kidney Int. Suppl. (2011)</italic>. <bold>12</bold>(1), 7&#8211;11 (2022).<pub-id pub-id-type="pmid">35529086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kisu.2021.11.003</pub-id><pub-id pub-id-type="pmcid">PMC9073222</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>A</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>PE</given-names></name></person-group><article-title>Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward</article-title><source>Kidney Int.</source><year>2014</year><volume>85</volume><issue>1</issue><fpage>49</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">24284513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.2013.444</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Levin, A. &amp; Stevens, P. E. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. <italic toggle="yes">Kidney Int.</italic><bold>85</bold>(1), 49&#8211;61 (2014).<pub-id pub-id-type="pmid">24284513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.2013.444</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Webster</surname><given-names>AC</given-names></name><name name-style="western"><surname>Nagler</surname><given-names>EV</given-names></name><name name-style="western"><surname>Morton</surname><given-names>RL</given-names></name><name name-style="western"><surname>Masson</surname><given-names>P</given-names></name></person-group><article-title>Chronic kidney disease</article-title><source>Lancet</source><year>2017</year><volume>389</volume><issue>10075</issue><fpage>1238</fpage><lpage>1252</lpage><pub-id pub-id-type="pmid">27887750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)32064-5</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Webster, A. C., Nagler, E. V., Morton, R. L. &amp; Masson, P. Chronic kidney disease. <italic toggle="yes">Lancet</italic> ;<bold>389</bold>(10075), 1238&#8211;1252. (2017).<pub-id pub-id-type="pmid">27887750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)32064-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>The</surname><given-names>E-K-C-G</given-names></name><etal/></person-group><article-title>Empagliflozin in patients with chronic kidney disease</article-title><source>N Engl. J. Med.</source><year>2023</year><volume>388</volume><issue>2</issue><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">36331190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2204233</pub-id><pub-id pub-id-type="pmcid">PMC7614055</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">The, E-K-C-G. et al. Empagliflozin in patients with chronic kidney disease. <italic toggle="yes">N Engl. J. Med.</italic><bold>388</bold>(2), 117&#8211;127 (2023).<pub-id pub-id-type="pmid">36331190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2204233</pub-id><pub-id pub-id-type="pmcid">PMC7614055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Identifying potential drug targets for idiopathic pulmonary fibrosis: a mendelian randomization study based on the druggable genes</article-title><source>Respir Res.</source><year>2024</year><volume>25</volume><issue>1</issue><fpage>217</fpage><pub-id pub-id-type="pmid">38783236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12931-024-02848-5</pub-id><pub-id pub-id-type="pmcid">PMC11118997</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Liu, Z. et al. Identifying potential drug targets for idiopathic pulmonary fibrosis: a mendelian randomization study based on the druggable genes. <italic toggle="yes">Respir Res.</italic><bold>25</bold>(1), 217 (2024).<pub-id pub-id-type="pmid">38783236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12931-024-02848-5</pub-id><pub-id pub-id-type="pmcid">PMC11118997</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Genetic insights into therapeutic targets for aortic aneurysms: A Mendelian randomization study</article-title><source>EBioMedicine</source><year>2022</year><volume>83</volume><fpage>104199</fpage><pub-id pub-id-type="pmid">35952493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2022.104199</pub-id><pub-id pub-id-type="pmcid">PMC9385553</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Chen, Y. et al. Genetic insights into therapeutic targets for aortic aneurysms: A Mendelian randomization study. <italic toggle="yes">EBioMedicine</italic><bold>83</bold>, 104199 (2022).<pub-id pub-id-type="pmid">35952493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2022.104199</pub-id><pub-id pub-id-type="pmcid">PMC9385553</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Storm, C. S. et al. International Parkinson&#8217;s Disease Finding genetically-supported drug targets for Parkinson&#8217;s disease using Mendelian randomization of the druggable genome. <italic toggle="yes">Nat. Commun.</italic><bold>12</bold>(1), 7342. (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-26280-1</pub-id><pub-id pub-id-type="pmcid">PMC8688480</pub-id><pub-id pub-id-type="pmid">34930919</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsson</surname><given-names>SC</given-names></name><name name-style="western"><surname>Butterworth</surname><given-names>AS</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name></person-group><article-title>Mendelian randomization for cardiovascular diseases: principles and applications</article-title><source>Eur. Heart J.</source><year>2023</year><volume>44</volume><issue>47</issue><fpage>4913</fpage><lpage>4924</lpage><pub-id pub-id-type="pmid">37935836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehad736</pub-id><pub-id pub-id-type="pmcid">PMC10719501</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Larsson, S. C., Butterworth, A. S. &amp; Burgess, S. Mendelian randomization for cardiovascular diseases: principles and applications. <italic toggle="yes">Eur. Heart J.</italic><bold>44</bold>(47), 4913&#8211;4924 (2023).<pub-id pub-id-type="pmid">37935836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehad736</pub-id><pub-id pub-id-type="pmcid">PMC10719501</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>MV</given-names></name></person-group><article-title>Meta-analysis and Mendelian randomization: A review</article-title><source>Res. Synth. Methods</source><year>2019</year><volume>10</volume><issue>4</issue><fpage>486</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">30861319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jrsm.1346</pub-id><pub-id pub-id-type="pmcid">PMC6973275</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Bowden, J. &amp; Holmes, M. V. Meta-analysis and Mendelian randomization: A review. <italic toggle="yes">Res. Synth. Methods</italic>. <bold>10</bold>(4), 486&#8211;496 (2019).<pub-id pub-id-type="pmid">30861319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jrsm.1346</pub-id><pub-id pub-id-type="pmcid">PMC6973275</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Birney, E. Mendelian randomization. <italic toggle="yes">Cold Spring Harb Perspect. Med.</italic> ;<bold>12</bold>(4). (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a041302</pub-id><pub-id pub-id-type="pmcid">PMC9121891</pub-id><pub-id pub-id-type="pmid">34872952</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emdin</surname><given-names>CA</given-names></name><name name-style="western"><surname>Khera</surname><given-names>AV</given-names></name><name name-style="western"><surname>Kathiresan</surname><given-names>S</given-names></name></person-group><article-title>Mendelian randomization</article-title><source>JAMA</source><year>2017</year><volume>318</volume><issue>19</issue><fpage>1925</fpage><lpage>1926</lpage><pub-id pub-id-type="pmid">29164242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.17219</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Emdin, C. A., Khera, A. V. &amp; Kathiresan, S. Mendelian randomization. <italic toggle="yes">JAMA</italic> ;<bold>318</bold>(19):1925&#8211;1926. (2017).<pub-id pub-id-type="pmid">29164242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.17219</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Finan, C. et al. The druggable genome and support for target identification and validation in drug development. <italic toggle="yes">Sci. Transl. Med.</italic> ;<bold>9</bold>(383). (2017).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aag1166</pub-id><pub-id pub-id-type="pmcid">PMC6321762</pub-id><pub-id pub-id-type="pmid">28356508</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vosa</surname><given-names>U</given-names></name><etal/></person-group><article-title>Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression</article-title><source>Nat. Genet.</source><year>2021</year><volume>53</volume><issue>9</issue><fpage>1300</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">34475573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00913-z</pub-id><pub-id pub-id-type="pmcid">PMC8432599</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Vosa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. <italic toggle="yes">Nat. Genet.</italic><bold>53</bold>(9), 1300&#8211;1310 (2021).<pub-id pub-id-type="pmid">34475573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00913-z</pub-id><pub-id pub-id-type="pmcid">PMC8432599</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurki</surname><given-names>MI</given-names></name><etal/></person-group><article-title>FinnGen provides genetic insights from a well-phenotyped isolated population</article-title><source>Nature</source><year>2023</year><volume>613</volume><issue>7944</issue><fpage>508</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">36653562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05473-8</pub-id><pub-id pub-id-type="pmcid">PMC9849126</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. <italic toggle="yes">Nature</italic><bold>613</bold>(7944), 508&#8211;518 (2023).<pub-id pub-id-type="pmid">36653562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05473-8</pub-id><pub-id pub-id-type="pmcid">PMC9849126</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gkatzionis</surname><given-names>A</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name><name name-style="western"><surname>Newcombe</surname><given-names>PJ</given-names></name></person-group><article-title>Statistical methods for cis-Mendelian randomization with two-sample summary-level data</article-title><source>Genet. Epidemiol.</source><year>2023</year><volume>47</volume><issue>1</issue><fpage>3</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">36273411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gepi.22506</pub-id><pub-id pub-id-type="pmcid">PMC7614127</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Gkatzionis, A., Burgess, S. &amp; Newcombe, P. J. Statistical methods for cis-Mendelian randomization with two-sample summary-level data. <italic toggle="yes">Genet. Epidemiol.</italic><bold>47</bold>(1), 3&#8211;25 (2023).<pub-id pub-id-type="pmid">36273411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gepi.22506</pub-id><pub-id pub-id-type="pmcid">PMC7614127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Using multiple genetic variants as instrumental variables for modifiable risk factors</article-title><source>Stat. Methods Med. Res.</source><year>2012</year><volume>21</volume><issue>3</issue><fpage>223</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">21216802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0962280210394459</pub-id><pub-id pub-id-type="pmcid">PMC3917707</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Palmer, T. M. et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. <italic toggle="yes">Stat. Methods Med. Res.</italic><bold>21</bold>(3), 223&#8211;242 (2012).<pub-id pub-id-type="pmid">21216802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0962280210394459</pub-id><pub-id pub-id-type="pmcid">PMC3917707</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name><name name-style="western"><surname>Dudbridge</surname><given-names>F</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>SG</given-names></name></person-group><article-title>Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods</article-title><source>Stat. Med.</source><year>2016</year><volume>35</volume><issue>11</issue><fpage>1880</fpage><lpage>1906</lpage><pub-id pub-id-type="pmid">26661904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.6835</pub-id><pub-id pub-id-type="pmcid">PMC4832315</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Burgess, S., Dudbridge, F. &amp; Thompson, S. G. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. <italic toggle="yes">Stat. Med.</italic><bold>35</bold>(11), 1880&#8211;1906 (2016).<pub-id pub-id-type="pmid">26661904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.6835</pub-id><pub-id pub-id-type="pmcid">PMC4832315</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemani</surname><given-names>G</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name></person-group><article-title>Evaluating the potential role of pleiotropy in Mendelian randomization studies</article-title><source>Hum. Mol. Genet.</source><year>2018</year><volume>27</volume><issue>R2</issue><fpage>R195</fpage><lpage>R208</lpage><pub-id pub-id-type="pmid">29771313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddy163</pub-id><pub-id pub-id-type="pmcid">PMC6061876</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Hemani, G., Bowden, J. &amp; Davey Smith, G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. <italic toggle="yes">Hum. Mol. Genet.</italic><bold>27</bold>(R2), R195&#8211;R208 (2018).<pub-id pub-id-type="pmid">29771313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddy163</pub-id><pub-id pub-id-type="pmcid">PMC6061876</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giambartolomei</surname><given-names>C</given-names></name><etal/></person-group><article-title>Bayesian test for colocalisation between pairs of genetic association studies using summary statistics</article-title><source>PLoS Genet.</source><year>2014</year><volume>10</volume><issue>5</issue><fpage>e1004383</fpage><pub-id pub-id-type="pmid">24830394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1004383</pub-id><pub-id pub-id-type="pmcid">PMC4022491</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. <italic toggle="yes">PLoS Genet.</italic><bold>10</bold>(5), e1004383 (2014).<pub-id pub-id-type="pmid">24830394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1004383</pub-id><pub-id pub-id-type="pmcid">PMC4022491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashburner</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gene ontology: tool for the unification of biology. The Gene Ontology Consortium</article-title><source>Nat. Genet.</source><year>2000</year><volume>25</volume><issue>1</issue><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">10802651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/75556</pub-id><pub-id pub-id-type="pmcid">PMC3037419</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. <italic toggle="yes">Nat. Genet.</italic><bold>25</bold>(1), 25&#8211;29 (2000).<pub-id pub-id-type="pmid">10802651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/75556</pub-id><pub-id pub-id-type="pmcid">PMC3037419</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Gene Ontology, C. et al. The Gene Ontology knowledgebase in 2023. <italic toggle="yes">Genetics</italic>. <bold>224</bold>(1). (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/genetics/iyad031</pub-id><pub-id pub-id-type="pmcid">PMC10158837</pub-id><pub-id pub-id-type="pmid">36866529</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M</given-names></name><name name-style="western"><surname>Furumichi</surname><given-names>M</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishiguro-Watanabe</surname><given-names>M</given-names></name></person-group><article-title>KEGG: biological systems database as a model of the real world</article-title><source>Nucleic Acids Res.</source><year>2025</year><volume>53</volume><issue>D1</issue><fpage>D672</fpage><lpage>D7</lpage><pub-id pub-id-type="pmid">39417505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkae909</pub-id><pub-id pub-id-type="pmcid">PMC11701520</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. &amp; Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. <italic toggle="yes">Nucleic Acids Res.</italic><bold>53</bold>(D1), D672&#8211;D7 (2025).<pub-id pub-id-type="pmid">39417505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkae909</pub-id><pub-id pub-id-type="pmcid">PMC11701520</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M</given-names></name></person-group><article-title>Toward understanding the origin and evolution of cellular organisms</article-title><source>Protein Sci.</source><year>2019</year><volume>28</volume><issue>11</issue><fpage>1947</fpage><lpage>1951</lpage><pub-id pub-id-type="pmid">31441146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pro.3715</pub-id><pub-id pub-id-type="pmcid">PMC6798127</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. <italic toggle="yes">Protein Sci.</italic><bold>28</bold>(11), 1947&#8211;1951 (2019).<pub-id pub-id-type="pmid">31441146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pro.3715</pub-id><pub-id pub-id-type="pmcid">PMC6798127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M</given-names></name><name name-style="western"><surname>Goto</surname><given-names>S</given-names></name></person-group><article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title><source>Nucleic Acids Res.</source><year>2000</year><volume>28</volume><issue>1</issue><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10592173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/28.1.27</pub-id><pub-id pub-id-type="pmcid">PMC102409</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Kanehisa, M. &amp; Goto, S. KEGG: kyoto encyclopedia of genes and genomes. <italic toggle="yes">Nucleic Acids Res.</italic><bold>28</bold>(1), 27&#8211;30 (2000).<pub-id pub-id-type="pmid">10592173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/28.1.27</pub-id><pub-id pub-id-type="pmcid">PMC102409</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gu</surname><given-names>L</given-names></name><name name-style="western"><surname>Eils</surname><given-names>R</given-names></name><name name-style="western"><surname>Schlesner</surname><given-names>M</given-names></name><name name-style="western"><surname>Brors</surname><given-names>B</given-names></name></person-group><article-title>circlize Implements and enhances circular visualization in R</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><issue>19</issue><fpage>2811</fpage><lpage>2812</lpage><pub-id pub-id-type="pmid">24930139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btu393</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Gu, Z., Gu, L., Eils, R., Schlesner, M. &amp; Brors, B. circlize Implements and enhances circular visualization in R. <italic toggle="yes">Bioinformatics</italic><bold>30</bold>(19), 2811&#8211;2812 (2014).<pub-id pub-id-type="pmid">24930139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btu393</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Methods in tubulin proteomics</article-title><source>Methods Cell. Biol.</source><year>2010</year><volume>95</volume><fpage>105</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">20466132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0091-679X(10)95007-3</pub-id><pub-id pub-id-type="pmcid">PMC4039033</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Miller, L. M. et al. Methods in tubulin proteomics. <italic toggle="yes">Methods Cell. Biol.</italic><bold>95</bold>, 105&#8211;126 (2010).<pub-id pub-id-type="pmid">20466132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0091-679X(10)95007-3</pub-id><pub-id pub-id-type="pmcid">PMC4039033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Goodson, H. V. &amp; Jonasson, E. M. Microtubules and microtubule-associated proteins. <italic toggle="yes">Cold Spring Harb. Perspect. Biol.</italic> ;<bold>10</bold>(6). (2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a022608</pub-id><pub-id pub-id-type="pmcid">PMC5983186</pub-id><pub-id pub-id-type="pmid">29858272</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Akhmanova</surname><given-names>A</given-names></name></person-group><article-title>Microtubule-organizing centers</article-title><source>Annu. Rev. Cell. Dev. Biol.</source><year>2017</year><volume>33</volume><fpage>51</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">28645217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-cellbio-100616-060615</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Wu, J. &amp; Akhmanova, A. Microtubule-organizing centers. <italic toggle="yes">Annu. Rev. Cell. Dev. Biol.</italic><bold>33</bold>, 51&#8211;75 (2017).<pub-id pub-id-type="pmid">28645217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-cellbio-100616-060615</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>TUBB, a robust biomarker with satisfying abilities in diagnosis, prognosis, and immune regulation via a comprehensive pan-cancer analysis</article-title><source>Front. Mol. Biosci.</source><year>2024</year><volume>11</volume><fpage>1365655</fpage><pub-id pub-id-type="pmid">38756529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2024.1365655</pub-id><pub-id pub-id-type="pmcid">PMC11096532</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Zhu, Z. et al. TUBB, a robust biomarker with satisfying abilities in diagnosis, prognosis, and immune regulation via a comprehensive pan-cancer analysis. <italic toggle="yes">Front. Mol. Biosci.</italic><bold>11</bold>, 1365655 (2024).<pub-id pub-id-type="pmid">38756529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2024.1365655</pub-id><pub-id pub-id-type="pmcid">PMC11096532</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Wordeman, L. &amp; Vicente, J. J. Microtubule targeting agents in disease: classic drugs, novel roles. <italic toggle="yes">Cancers</italic>. <bold>13</bold>(22). (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13225650</pub-id><pub-id pub-id-type="pmcid">PMC8616087</pub-id><pub-id pub-id-type="pmid">34830812</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchison</surname><given-names>TJ</given-names></name></person-group><article-title>Localization of an exchangeable GTP binding site at the plus end of microtubules</article-title><source>Science</source><year>1993</year><volume>261</volume><issue>5124</issue><fpage>1044</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">8102497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.8102497</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Mitchison, T. J. Localization of an exchangeable GTP binding site at the plus end of microtubules. <italic toggle="yes">Science</italic><bold>261</bold>(5124), 1044&#8211;1047 (1993).<pub-id pub-id-type="pmid">8102497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.8102497</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>RL</given-names></name><name name-style="western"><surname>Pettit</surname><given-names>GR</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>E</given-names></name></person-group><article-title>Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites</article-title><source>J. Biol. Chem.</source><year>1990</year><volume>265</volume><issue>28</issue><fpage>17141</fpage><lpage>17149</lpage><pub-id pub-id-type="pmid">2211617</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Bai, R. L., Pettit, G. R. &amp; Hamel, E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. <italic toggle="yes">J. Biol. Chem.</italic><bold>265</bold>(28), 17141&#8211;17149 (1990).<pub-id pub-id-type="pmid">2211617</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>R</given-names></name><name name-style="western"><surname>Pettit</surname><given-names>GR</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>E</given-names></name></person-group><article-title>Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain</article-title><source>Biochem. Pharmacol.</source><year>1990</year><volume>39</volume><issue>12</issue><fpage>1941</fpage><lpage>1949</lpage><pub-id pub-id-type="pmid">2353935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-2952(90)90613-p</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Bai, R., Pettit, G. R. &amp; Hamel, E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. <italic toggle="yes">Biochem. Pharmacol.</italic><bold>39</bold>(12), 1941&#8211;1949 (1990).<pub-id pub-id-type="pmid">2353935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-2952(90)90613-p</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamel</surname><given-names>E</given-names></name></person-group><article-title>Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B</article-title><source>Pharmacol. Ther.</source><year>1992</year><volume>55</volume><issue>1</issue><fpage>31</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">1287674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0163-7258(92)90028-x</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Hamel, E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. <italic toggle="yes">Pharmacol. Ther.</italic><bold>55</bold>(1), 31&#8211;51 (1992).<pub-id pub-id-type="pmid">1287674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0163-7258(92)90028-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravelli</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</article-title><source>Nature</source><year>2004</year><volume>428</volume><issue>6979</issue><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">15014504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature02393</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ravelli, R. B. et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. <italic toggle="yes">Nature</italic><bold>428</bold>(6979), 198&#8211;202 (2004).<pub-id pub-id-type="pmid">15014504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature02393</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nogales</surname><given-names>E</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>SG</given-names></name><name name-style="western"><surname>Downing</surname><given-names>KH</given-names></name></person-group><article-title>Structure of the alpha beta tubulin dimer by electron crystallography</article-title><source>Nature</source><year>1998</year><volume>391</volume><issue>6663</issue><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">9428769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/34465</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Nogales, E., Wolf, S. G. &amp; Downing, K. H. Structure of the alpha beta tubulin dimer by electron crystallography. <italic toggle="yes">Nature</italic><bold>391</bold>(6663), 199&#8211;203 (1998).<pub-id pub-id-type="pmid">9428769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/34465</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rhizoxin binding to tubulin at the maytansine-binding site</article-title><source>Biochim. Biophys. Acta</source><year>1987</year><volume>926</volume><issue>3</issue><fpage>215</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">3120782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0304-4165(87)90206-6</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Takahashi, M. et al. Rhizoxin binding to tubulin at the maytansine-binding site. <italic toggle="yes">Biochim. Biophys. Acta</italic>. <bold>926</bold>(3), 215&#8211;223 (1987).<pub-id pub-id-type="pmid">3120782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0304-4165(87)90206-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prota</surname><given-names>AE</given-names></name><etal/></person-group><article-title>A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</article-title><source>Proc. Natl. Acad. Sci. U S A</source><year>2014</year><volume>111</volume><issue>38</issue><fpage>13817</fpage><lpage>13821</lpage><pub-id pub-id-type="pmid">25114240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1408124111</pub-id><pub-id pub-id-type="pmcid">PMC4183314</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Prota, A. E. et al. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. <italic toggle="yes">Proc. Natl. Acad. Sci. U S A</italic>. <bold>111</bold>(38), 13817&#8211;13821 (2014).<pub-id pub-id-type="pmid">25114240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1408124111</pub-id><pub-id pub-id-type="pmcid">PMC4183314</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prota</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Structural basis of microtubule stabilization by laulimalide and peloruside A</article-title><source>Angew Chem. Int. Ed. Engl.</source><year>2014</year><volume>53</volume><issue>6</issue><fpage>1621</fpage><lpage>1625</lpage><pub-id pub-id-type="pmid">24470331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201307749</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Prota, A. E. et al. Structural basis of microtubule stabilization by laulimalide and peloruside A. <italic toggle="yes">Angew Chem. Int. Ed. Engl.</italic><bold>53</bold>(6), 1621&#8211;1625 (2014).<pub-id pub-id-type="pmid">24470331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201307749</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hood</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity</article-title><source>Cancer Res.</source><year>2002</year><volume>62</volume><issue>12</issue><fpage>3356</fpage><lpage>3360</lpage><pub-id pub-id-type="pmid">12067973</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Hood, K. A. et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity. <italic toggle="yes">Cancer Res.</italic><bold>62</bold>(12), 3356&#8211;3360 (2002).<pub-id pub-id-type="pmid">12067973</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Matthew, S. et al. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site. <italic toggle="yes">Proc. Natl. Acad. Sci. U S A</italic> ;<bold>118</bold>(9). (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2021847118</pub-id><pub-id pub-id-type="pmcid">PMC7936326</pub-id><pub-id pub-id-type="pmid">33619102</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Yang, J. et al. Cevipabulin-tubulin complex reveals a novel agent binding site on alpha-tubulin with tubulin degradation effect. <italic toggle="yes">Sci. Adv.</italic> ;<bold>7</bold>(21). (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abg4168</pub-id><pub-id pub-id-type="pmcid">PMC8133757</pub-id><pub-id pub-id-type="pmid">34138737</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>L</given-names></name></person-group><article-title>Microtubules as a target for anticancer drugs</article-title><source>Nat. Rev. Cancer</source><year>2004</year><volume>4</volume><issue>4</issue><fpage>253</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15057285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1317</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Jordan, M. A. &amp; Wilson, L. Microtubules as a target for anticancer drugs. <italic toggle="yes">Nat. Rev. Cancer</italic>. <bold>4</bold>(4), 253&#8211;265 (2004).<pub-id pub-id-type="pmid">15057285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1317</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Role of JNK activation in paclitaxel-induced apoptosis in human head and neck squamous cell carcinoma</article-title><source>Oncol. Lett.</source><year>2021</year><volume>22</volume><issue>4</issue><fpage>705</fpage><pub-id pub-id-type="pmid">34457060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2021.12966</pub-id><pub-id pub-id-type="pmcid">PMC8358625</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Lan, Y. Y. et al. Role of JNK activation in paclitaxel-induced apoptosis in human head and neck squamous cell carcinoma. <italic toggle="yes">Oncol. Lett.</italic><bold>22</bold>(4), 705 (2021).<pub-id pub-id-type="pmid">34457060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2021.12966</pub-id><pub-id pub-id-type="pmcid">PMC8358625</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fennell</surname><given-names>B</given-names></name><etal/></person-group><article-title>Microtubules as antiparasitic drug targets</article-title><source>Expert Opin. Drug Discov</source><year>2008</year><volume>3</volume><issue>5</issue><fpage>501</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">23484923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17460441.3.5.501</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Fennell, B. et al. Microtubules as antiparasitic drug targets. <italic toggle="yes">Expert Opin. Drug Discov</italic>. <bold>3</bold>(5), 501&#8211;518 (2008).<pub-id pub-id-type="pmid">23484923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17460441.3.5.501</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JI</given-names></name><name name-style="western"><surname>Park</surname><given-names>KM</given-names></name></person-group><article-title>Inhibition of microtubule dynamics impedes repair of kidney ischemia/reperfusion injury and increases fibrosis</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>27775</fpage><pub-id pub-id-type="pmid">27270990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep27775</pub-id><pub-id pub-id-type="pmcid">PMC4897697</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Han, S. J., Kim, J. H., Kim, J. I. &amp; Park, K. M. Inhibition of microtubule dynamics impedes repair of kidney ischemia/reperfusion injury and increases fibrosis. <italic toggle="yes">Sci. Rep.</italic><bold>6</bold>, 27775 (2016).<pub-id pub-id-type="pmid">27270990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep27775</pub-id><pub-id pub-id-type="pmcid">PMC4897697</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Identification of potential serum proteomic biomarkers for clear cell renal cell carcinoma</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>11</issue><fpage>e111364</fpage><pub-id pub-id-type="pmid">25368985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0111364</pub-id><pub-id pub-id-type="pmcid">PMC4219714</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Yang, J. et al. Identification of potential serum proteomic biomarkers for clear cell renal cell carcinoma. <italic toggle="yes">PLoS One</italic>. <bold>9</bold>(11), e111364 (2014).<pub-id pub-id-type="pmid">25368985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0111364</pub-id><pub-id pub-id-type="pmcid">PMC4219714</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Wang, Y., Hu, L., Zhou, D., Chen, X. &amp; Zhou, L. Association of urinary biomarkers of renal tubular injury with cognitive dysfunction in older patients with chronic kidney disease: a cross-sectional observational study. <italic toggle="yes">Brain Sci.</italic><bold>13</bold>(4). (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci13040551</pub-id><pub-id pub-id-type="pmcid">PMC10136492</pub-id><pub-id pub-id-type="pmid">37190516</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Promotion of inflammation, apoptosis, and inhibition of autophagy by overexpression of lncRNA SNHG12 in acute kidney injury</article-title><source>Iran. J. Kidney Dis.</source><year>2024</year><volume>1</volume><issue>1</issue><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">38308550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.52547/ijkd.7903</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Zhang, J. et al. Promotion of inflammation, apoptosis, and inhibition of autophagy by overexpression of lncRNA SNHG12 in acute kidney injury. <italic toggle="yes">Iran. J. Kidney Dis.</italic><bold>1</bold>(1), 45&#8211;55 (2024).<pub-id pub-id-type="pmid">38308550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.52547/ijkd.7903</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>